Jason Crenshaw
Family · Topeka, KSNPI 1952605321
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 368 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 368 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$844
- E.r. Squibb & Sons, L.L.C.$836
- AbbVie$771
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$630
- Johnson & Johnson$568
- plus $2K from 7 others
What the payments were for
- Food & beverage$6,47599%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 61 | $1,079 |
| Otsuka America Pharmaceutical, Inc. | 44 | $844 |
| E.r. Squibb & Sons, L.L.C. | 37 | $836 |
| AbbVie | 50 | $771 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $630 |
| Johnson & Johnson | 42 | $568 |
| Lundbeck LLC | 32 | $558 |
| Teva Pharmaceuticals USA, Inc. | 31 | $384 |
| Axsome Therapeutics, Inc. | 15 | $347 |
| Vanda Pharmaceuticals Inc. | 6 | $171 |
| Neurocrine Biosciences, Inc. | 8 | $166 |
| Indivior Inc. | 7 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,521 in reported general payments places this provider in the 95th percentile of 1,579 family providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 54 | $188,227 |
| AristadaAripiprazole Lauroxil | 30 | $102,520 |
| VraylarCariprazine Hcl | 51 | $74,053 |
| Abilify MaintenaAripiprazole | 25 | $72,182 |
| CaplytaLumateperone Tosylate | 43 | $68,781 |
| SpravatoEsketamine Hcl | 59 | $68,763 |
| PerserisRisperidone | 13 | $41,581 |
| LybalviOlanzapine/Samidorphan Malate | 27 | $39,739 |
| Paliperidone ErPaliperidone | 56 | $29,575 |
| RexultiBrexpiprazole | 18 | $28,043 |
| TrintellixVortioxetine Hydrobromide | 37 | $18,790 |
| Aripiprazole | 111 | $13,901 |
| Lurasidone Hcl | 53 | $13,188 |
| AuvelityDextromethorphan Hbr/Bupropion | 17 | $12,898 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 39 | $6,875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Spravato | $568 | $256,990113 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,079 | $142,25957 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $844 | $100,22643 claims |
| AbbVieVraylar | $771 | $74,05351 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $630 | $68,78143 claims |
| Indivior Inc.Perseris | $121 | $41,58113 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $45 | $18,79037 claims |
| Axsome Therapeutics, Inc.Auvelity | $347 | $12,89817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,579 family providers in Kansas.
Other family in Topeka
- Tatum TolandTopeka$108K
- Ansley McKennaTopeka$8K
- Zohra HussainiKansas City$329K
- Jennifer ChesterOverland Park$327K
- Amanda CaldwellLeawood$203K
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Mary GonzalesWichita$87K
- Erin FeitzOverland Park$36K
- Adam CaseKansas City$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.